INT228870

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.51
First Reported 2008
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 17
Total Number 25
Disease Relevance 20.97
Pain Relevance 8.77

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (Lpar1) plasma membrane (Lpar1) cytoplasm (Lpar1)
signal transducer activity (Lpar1)
Anatomy Link Frequency
nerve 8
plasma 2
dendrite 1
sciatic nerve 1
fibroblast 1
Lpar1 (Mus musculus)
Pain Link Frequency Relevance Heat
antagonist 150 100.00 Very High Very High Very High
Spinal cord 112 100.00 Very High Very High Very High
allodynia 98 99.90 Very High Very High Very High
Hyperalgesia 23 99.68 Very High Very High Very High
cva 9 99.56 Very High Very High Very High
Neuropathic pain 290 99.12 Very High Very High Very High
Sciatic nerve 64 99.12 Very High Very High Very High
fibrosis 81 98.84 Very High Very High Very High
Thermal hyperalgesia 43 98.46 Very High Very High Very High
Brush evoked pain 48 98.22 Very High Very High Very High
Disease Link Frequency Relevance Heat
Neuropathic Pain 447 99.90 Very High Very High Very High
Cancer 364 99.84 Very High Very High Very High
Hyperalgesia 66 99.68 Very High Very High Very High
Cv General 3 Under Development 12 99.56 Very High Very High Very High
Disorder Of Lipid Metabolism 288 99.34 Very High Very High Very High
Nervous System Injury 303 99.26 Very High Very High Very High
Congenital Anomalies 42 98.96 Very High Very High Very High
Fibrosis 55 98.84 Very High Very High Very High
Metastasis 204 98.80 Very High Very High Very High
Thrombosis 38 98.64 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
As expected, the LPA level in SC and DR of atx+/- mice was decreased to 38 and 50% of control (WT) mice, respectively, suggesting that LPC is converted to LPA by the action of endogenous ATX.
Negative_regulation (decreased) of LPA associated with spinal cord
1) Confidence 0.51 Published 2009 Journal Mol Pain Section Body Doc Link PMC2780384 Disease Relevance 0.17 Pain Relevance 0.37
In addition, mice lacking the LPA1 receptor gene (lpa1-/- mice) lost these nerve injury-induced neuropathic pain behaviors and phenomena.
Negative_regulation (lacking) of LPA1 receptor in nerve associated with nervous system injury and neuropathic pain
2) Confidence 0.43 Published 2008 Journal Mol Pain Section Abstract Doc Link PMC2277392 Disease Relevance 1.21 Pain Relevance 0.75
Therefore, targeted inhibition of LPA biosynthesis as well as LPA1 receptor would be a valuable way to prevent nerve injury-induced neuropathic pain.
Negative_regulation (inhibition) of LPA1 receptor in nerve associated with nervous system injury and neuropathic pain
3) Confidence 0.43 Published 2008 Journal Mol Pain Section Body Doc Link PMC2277392 Disease Relevance 1.36 Pain Relevance 0.74
Mice lacking LPA1 receptor do not develop any signs of neuropathic pain, demyelination or upregulation of pain-related gene/protein expression following nerve injury [5].
Negative_regulation (lacking) of LPA1 receptor in nerve associated with pain, demyelination, nervous system injury and neuropathic pain
4) Confidence 0.43 Published 2008 Journal Mol Pain Section Body Doc Link PMC2277392 Disease Relevance 0.97 Pain Relevance 0.58
We previously reported that i.t. injection of an antisense oligonucleotide for LPA1 receptor or inhibitors of RhoA/ROCK, one of the downstream signaling molecules of LPA1 receptor, completely abolished nerve injury-induced neuropathic pain [5].
Negative_regulation (inhibitors) of LPA1 receptor in nerve associated with nervous system injury and neuropathic pain
5) Confidence 0.43 Published 2008 Journal Mol Pain Section Body Doc Link PMC2277392 Disease Relevance 1.24 Pain Relevance 0.87
Therefore, targeted inhibition of ATX-mediated LPA biosynthesis as well as LPA1 receptor and its downstream pathways may represent a novel way to prevent nerve injury-induced neuropathic pain.



Negative_regulation (inhibition) of LPA1 receptor in nerve associated with nervous system injury and neuropathic pain
6) Confidence 0.43 Published 2008 Journal Mol Pain Section Body Doc Link PMC2277392 Disease Relevance 1.09 Pain Relevance 0.71
Therefore, targeted inhibition of ATX-mediated LPA biosynthesis as well as LPA1 receptor and its downstream pathways may represent a novel way to prevent nerve injury-induced neuropathic pain.



Negative_regulation (inhibition) of LPA1 receptor in nerve associated with nervous system injury and neuropathic pain
7) Confidence 0.43 Published 2008 Journal Mol Pain Section Abstract Doc Link PMC2277392 Disease Relevance 1.20 Pain Relevance 0.71
The hyperalgesia was completely abolished in lpa1-/- mice, and reduced by 50% in atx+/- mice.
Negative_regulation (abolished) of lpa1 associated with hyperalgesia
8) Confidence 0.43 Published 2008 Journal Mol Pain Section Abstract Doc Link PMC2277392 Disease Relevance 1.22 Pain Relevance 0.72
Niacin raises HDL-C levels by reducing the fractional catabolic rate of Apo AI containing HDL-C particles, decreasing hepatic removal of lipoprotein A-I (LpA-I) (a cardioprotective subfraction of HDL-C without Apo AII), and inhibiting removal of Apo AI without affecting HDL cholesterol ester (Jin et al 1997); resulting in an increase of Apo AI enriched, pre-?
Negative_regulation (removal) of LpA-I associated with disorder of lipid metabolism
9) Confidence 0.42 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2464766 Disease Relevance 1.56 Pain Relevance 0.03
These investigators showed that patients with idiopathic pulmonary fibrosis, had increased LPA levels in bronchoalveolar lavage fluid and that inhibition of LPA1 reduced fibroblast responses to the chemotactic activity of the lavage fluid.
Negative_regulation (inhibition) of LPA1 in fibroblast associated with fibrosis and pulmonary fibrosis
10) Confidence 0.38 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2989581 Disease Relevance 0.88 Pain Relevance 0.31
However, these antagonists also inhibit LPA1.
Negative_regulation (inhibit) of LPA1 associated with antagonist
11) Confidence 0.38 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2989581 Disease Relevance 0.50 Pain Relevance 0.15
These include skeletal and craniofacial abnormalities (Lpar1, Pitx2, Satb2, Tcof1, Trps1); heart defects (Adm, Cited2, Cxcl12, Gja1, Hey2, Pitx2, Mef2c); reduced body size (Ebf1, Lpar1, Hsd3b7, Mef2c); decreased adiposity (Cebpb, Ebf1, Lpar1, Npy, Vldlr); behavioral abnormalities (Avpr1a, Ctnnd2, Lpar1, Vldlr); seizures (Cdk5r1, Gabrb1, Gabrb2, Neto1, Nr4a3, Plcb1, S100b, Sv2b); and hearing deficits (Cldn11, Eya, Gjb2, Gjb6) [66], [92]–[124].
Negative_regulation (decreased) of Lpar1 in heart associated with convulsion, congenital anomalies, heart defects and craniofacial abnormalities
12) Confidence 0.38 Published 2009 Journal PLoS Genetics Section Body Doc Link PMC2730539 Disease Relevance 0.60 Pain Relevance 0
I.t. injection of LPA (1 nmol) caused a time-dependent increase in LPA levels in the SC and DR that lasted until 3 h post-treatment, followed by a slight decline in LPA levels at 5 h.
Negative_regulation (decline) of LPA associated with spinal cord
13) Confidence 0.37 Published 2009 Journal Mol Pain Section Body Doc Link PMC2780384 Disease Relevance 0.18 Pain Relevance 0.14
-fiber stimulation in mice with partial sciatic nerve injury [8], and this type of allodynia was abolished in Lpar1-/- mice [11].
Negative_regulation (abolished) of Lpar1 in sciatic nerve associated with nervous system injury, allodynia and sciatic nerve
14) Confidence 0.37 Published 2008 Journal Mol Pain Section Body Doc Link PMC2599895 Disease Relevance 1.39 Pain Relevance 0.77
On day 7 after the sham or nerve injury operation, significant thermal hyperalgesia and mechanical allodynia were observed in wild-type mice, which were mostly abolished in Lpar1-/- mice [10].
Negative_regulation (abolished) of Lpar1 in nerve associated with nervous system injury, allodynia and thermal hyperalgesia
15) Confidence 0.37 Published 2008 Journal Mol Pain Section Body Doc Link PMC2599895 Disease Relevance 0.79 Pain Relevance 0.43
Moreover, the treatment of cells with Ki16425, an antagonist of LPA1 and LPA3 receptors, totally blocked autotaxin-dependent but not LPC-dependent cell proliferation (Figure 1C).
Negative_regulation (antagonist) of LPA1 associated with antagonist
16) Confidence 0.35 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2840030 Disease Relevance 0.16 Pain Relevance 0.05
PCR reactions were run using SYBR® Green qPCR kit and sets of specific primers, LPA1-F (5?
Negative_regulation (using) of LPA1
17) Confidence 0.35 Published 2010 Journal PLoS ONE Section Body Doc Link PMC2840030 Disease Relevance 0 Pain Relevance 0
In adult mice, ATX overexpression leads to haemorrhages due to an inhibitory effect of LPA on platelets, whereas ATX ± heterozygotes, which have a reduced plasma LPA concentration, are more prone to thrombosis (Pamuklar et al., 2009).
Negative_regulation (reduced) of LPA in plasma associated with cva and thrombosis
18) Confidence 0.33 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2989581 Disease Relevance 0.47 Pain Relevance 0.05
In several models, inhibition of the LPA1 receptor inhibits the progression of fibrosis (Pradere et al., 2007; Tager et al., 2008), but LPA-induced ?
Negative_regulation (inhibition) of LPA1 receptor associated with fibrosis
19) Confidence 0.28 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2989581 Disease Relevance 1.08 Pain Relevance 0.28
Silencing expression or utilizing pharmacological inhibition of LPA1 in cancer cells reduces bone metastasis progression.
Negative_regulation (inhibition) of LPA1 associated with cancer and metastasis
20) Confidence 0.28 Published 2010 Journal British Journal of Pharmacology Section Body Doc Link PMC2989581 Disease Relevance 1.08 Pain Relevance 0.04

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox